The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
209
The proportion of subjects achieving an erythroid response during the 13-week test period
The proportion of subjects achieving an erythroid response during the 28-week treatment period
The change in Hb from baseline
The incidence of red blood cell (RBC) transfusions (greater than or equal to 1 unit)
The change in FACT-F from baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.